TY - JOUR
T1 - Structure Activity Relationships for a Series of Eticlopride-Based Dopamine D2/D3Receptor Bitopic Ligands
AU - Shaik, Anver Basha
AU - Boateng, Comfort A.
AU - Battiti, Francisco O.
AU - Bonifazi, Alessandro
AU - Cao, Jianjing
AU - Chen, Li
AU - Chitsazi, Rezvan
AU - Ravi, Saiprasad
AU - Lee, Kuo Hao
AU - Shi, Lei
AU - Newman, Amy Hauck
N1 - Publisher Copyright:
© Not subject to U.S. Copyright. Published 2021 by American Chemical Society.
PY - 2021/10/28
Y1 - 2021/10/28
N2 - The crystal structure of the dopamine D3 receptor (D3R) in complex with eticlopride inspired the design of bitopic ligands that explored (1) N-alkylation of the eticlopride's pyrrolidine ring, (2) shifting of the position of the pyrrolidine nitrogen, (3) expansion of the pyrrolidine ring system, and (4) incorporation of O-alkylations at the 4-position. Structure activity relationships (SAR) revealed that moving the N- or expanding the pyrrolidine ring was detrimental to D2R/D3R binding affinities. Small pyrrolidine N-alkyl groups were poorly tolerated, but the addition of a linker and secondary pharmacophore (SP) improved affinities. Moreover, O-alkylated analogues showed higher binding affinities compared to analogously N-alkylated compounds, e.g., O-alkylated 33 (D3R, 0.436 nM and D2R, 1.77 nM) vs the N-alkylated 11 (D3R, 6.97 nM and D2R, 25.3 nM). All lead molecules were functional D2R/D3R antagonists. Molecular models confirmed that 4-position modifications would be well-tolerated for future D2R/D3R bioconjugate tools that require long linkers and or sterically bulky groups.
AB - The crystal structure of the dopamine D3 receptor (D3R) in complex with eticlopride inspired the design of bitopic ligands that explored (1) N-alkylation of the eticlopride's pyrrolidine ring, (2) shifting of the position of the pyrrolidine nitrogen, (3) expansion of the pyrrolidine ring system, and (4) incorporation of O-alkylations at the 4-position. Structure activity relationships (SAR) revealed that moving the N- or expanding the pyrrolidine ring was detrimental to D2R/D3R binding affinities. Small pyrrolidine N-alkyl groups were poorly tolerated, but the addition of a linker and secondary pharmacophore (SP) improved affinities. Moreover, O-alkylated analogues showed higher binding affinities compared to analogously N-alkylated compounds, e.g., O-alkylated 33 (D3R, 0.436 nM and D2R, 1.77 nM) vs the N-alkylated 11 (D3R, 6.97 nM and D2R, 25.3 nM). All lead molecules were functional D2R/D3R antagonists. Molecular models confirmed that 4-position modifications would be well-tolerated for future D2R/D3R bioconjugate tools that require long linkers and or sterically bulky groups.
UR - http://www.scopus.com/inward/record.url?scp=85118169554&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118169554&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.1c01353
DO - 10.1021/acs.jmedchem.1c01353
M3 - Article
C2 - 34636551
AN - SCOPUS:85118169554
SN - 0022-2623
VL - 64
SP - 15313
EP - 15333
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 20
ER -